U.S. FDA grants NeuroRx Inc Investigational New Drug permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 to prevent progression to respiratory failure

Company claims aviptadil (synthetic human Vasoactive Intestinal Polypeptide) is first COVID therapeutic shown to block replication of SARS-CoV-2 virus in human lung cells and monocytes while also preventing synthesis of cytokines in lung. Trial is expected to begin by September.


Reuters Health